Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOEL CHRISTOPHER JOYCE

Allopathic & Osteopathic Physicians Dermatology Pediatric Dermatology

NPI
1700045713
CMS profile
77679
Location
SKOKIE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$2,376.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $2,376.00 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
GENZYME CORPORATION $2,376.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOEL CHRISTOPHER JOYCE

NPI 1700045713 · CMS profile ID 77679

Allopathic & Osteopathic Physicians / Dermatology / Pediatric Dermatology

SKOKIE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700045713?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOEL CHRISTOPHER JOYCE, NPI 1700045713, CMS profile ID 77679. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700045713?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JOEL CHRISTOPHER JOYCE, NPI 1700045713, CMS profile ID 77679. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700045713?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JOEL CHRISTOPHER JOYCE, NPI 1700045713, CMS profile ID 77679, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1700045713?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $2,376.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $2,376.0007/20/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744016853 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $700.40 2
PY2020 $2,376.00 1
PY2021 $2,246.65 3
PY2022 $2,632.70 9
PY2023 $23,671.61 40
PY2024 $79,055.13 79
PY2025 $92,566.63 73

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,750.00 4
PY2025 Principal investigator $694,810.55 184
PY2024 Recipient $7,148.03 20
PY2024 Principal investigator $657,792.45 167
PY2023 Recipient $3,281.97 14
PY2023 Principal investigator $421,779.06 92
PY2022 Recipient $1,517.38 3
PY2022 Principal investigator $234,287.76 66
PY2021 Principal investigator $111,180.61 56
PY2020 Principal investigator $343,493.78 70
PY2019 Principal investigator $4,975.53 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

106 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $2,480.00 12/22/2023 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 23 TWOPART STUDY TO EVALUATE THE EFFICACY AND LONGTERM SAFETY WITH ORAL ETRASIMOD 2 MG ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATETOSEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRIOR SYSTEMIC TREATMENT FAILURE No dispute reported 06/30/2026 1046014925
Principal investigator 1 SANOFI US SERVICES INC. $897.35 12/22/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1036005671
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/22/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1036005681
Principal investigator 1 PFIZER INC. $2,713.00 12/09/2023 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 23 TWOPART STUDY TO EVALUATE THE EFFICACY AND LONGTERM SAFETY WITH ORAL ETRASIMOD 2 MG ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATETOSEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRIOR SYSTEMIC TREATMENT FAILURE No dispute reported 06/30/2026 1046118605
Recipient SANOFI US SERVICES INC. $5.98 12/04/2023 Covered Recipient Physician Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1035919437
Recipient SANOFI US SERVICES INC. $26.20 12/04/2023 Covered Recipient Physician Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1035919447
Recipient SANOFI US SERVICES INC. $84.00 12/04/2023 Covered Recipient Physician Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1035919477
Principal investigator 1 Janssen Research & Development, LLC $10,722.56 11/17/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 986113557
Principal investigator 1 Incyte Corporation $6,220.80 11/16/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1040666357
Recipient SANOFI US SERVICES INC. $260.36 11/15/2023 Covered Recipient Physician Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1035919507
Recipient SANOFI US SERVICES INC. $263.04 11/15/2023 Covered Recipient Physician Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1035919515
Recipient SANOFI US SERVICES INC. $479.12 11/15/2023 Covered Recipient Physician Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1035919525
Recipient SANOFI US SERVICES INC. $60.00 11/14/2023 Covered Recipient Physician Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1035919457
Recipient SANOFI US SERVICES INC. $75.01 11/14/2023 Covered Recipient Physician Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1035919467
Recipient SANOFI US SERVICES INC. $124.94 11/14/2023 Covered Recipient Physician Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1035919485
Recipient SANOFI US SERVICES INC. $153.32 11/14/2023 Covered Recipient Physician Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1035919497
Principal investigator 1 Eli Lilly and Company $19,500.00 11/02/2023 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 3 DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1038062349
Principal investigator 1 Incyte Corporation $4,215.94 11/01/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040912247
Principal investigator 1 Janssen Research & Development, LLC $8,928.56 10/28/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 986113549
Principal investigator 1 Janssen Research & Development, LLC $11,178.56 10/28/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 986113553
Principal investigator 1 Amgen Inc. $5,511.52 10/20/2023 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
P3 AD Adult Combo TCS No dispute reported 06/30/2026 1029654041
Principal investigator 1 Incyte Corporation $671.00 10/19/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1040666341
Principal investigator 1 Janssen Research & Development, LLC $1,656.00 10/17/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 986113561
Principal investigator 1 Eli Lilly and Company $2,825.00 10/13/2023 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1038065399
Principal investigator 1 Incyte Corporation $163.68 10/12/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040912195
Recipient GENZYME CORPORATION $500.00 10/11/2023 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1035919427
Principal investigator 1 Incyte Corporation $1,988.84 10/04/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040912183
Principal investigator 1 SANOFI US SERVICES INC. $897.35 10/02/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1036005691
Principal investigator 1 SANOFI US SERVICES INC. $394.10 10/02/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1036005701
Principal investigator 1 SANOFI US SERVICES INC. $394.10 10/02/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1036005711
Principal investigator 1 SANOFI US SERVICES INC. $394.10 10/02/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1036005721
Principal investigator 1 SANOFI US SERVICES INC. $394.10 10/02/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1036005729
Principal investigator 1 SANOFI US SERVICES INC. $394.10 10/02/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1036005741
Principal investigator 1 Incyte Corporation $1,698.00 09/26/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1040666275
Principal investigator 1 Incyte Corporation $6,220.80 09/21/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1040666259
Principal investigator 1 Janssen Research & Development, LLC $18,809.76 09/15/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 986113545
Principal investigator 1 Incyte Corporation $491.04 09/08/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040912135
Principal investigator 1 Incyte Corporation $473.00 09/06/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040863527
Recipient GENZYME CORPORATION $500.00 09/05/2023 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1035919357
Recipient GENZYME CORPORATION $250.00 09/05/2023 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1035919377
Principal investigator 1 Incyte Corporation $4,268.62 08/30/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040912073
Principal investigator 1 Incyte Corporation $433.00 08/24/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040912045
Principal investigator 1 Incyte Corporation $9,331.20 08/17/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1040666227
Principal investigator 1 Incyte Corporation $2,058.00 08/17/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1040666243
Principal investigator 1 ABBVIE INC. $176.80 08/16/2023 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 998359733
Principal investigator 1 ABBVIE INC. $2,361.08 08/10/2023 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 998359729
Principal investigator 1 PFIZER INC. $500.00 08/05/2023 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AN INTERVENTIONAL PK PD PHASE 1 OPENLABEL STUDY TO INVESTIGATE PK AND PD OF MULTIPLEDOSE RITLECITINIB IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1046153761
Principal investigator 1 Incyte Corporation $41,094.00 08/03/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1040666211
Principal investigator 1 Incyte Corporation $7,623.06 08/02/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040912059
Principal investigator 1 PFIZER INC. $16,250.00 07/26/2023 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A PHASE 23 TWOPART STUDY TO EVALUATE THE EFFICACY AND LONGTERM SAFETY WITH ORAL ETRASIMOD 2 MG ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATETOSEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRIOR SYSTEMIC TREATMENT FAILURE No dispute reported 06/30/2026 1045997271
Principal investigator 1 Incyte Corporation $1,300.20 07/20/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040911845
Principal investigator 1 Janssen Research & Development, LLC $8,449.92 07/14/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 986113541
Principal investigator 1 Janssen Research & Development, LLC $1,246.00 07/10/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 986145545
Principal investigator 1 Incyte Corporation $4,715.05 07/06/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040911833
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/27/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1036005517
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/27/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1036005525
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/27/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1036005535
Principal investigator 1 SANOFI US SERVICES INC. $394.10 06/27/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1036005547
Principal investigator 1 PFIZER INC. $12,000.00 06/22/2023 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AN INTERVENTIONAL PK PD PHASE 1 OPENLABEL STUDY TO INVESTIGATE PK AND PD OF MULTIPLEDOSE RITLECITINIB IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1046133163
Principal investigator 1 Janssen Research & Development, LLC $12,930.56 06/20/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 986113537
Principal investigator 1 Incyte Corporation $1,698.00 06/15/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1040666045
Recipient GENZYME CORPORATION $500.00 06/09/2023 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1035919367
Principal investigator 1 Janssen Research & Development, LLC $1,750.00 06/09/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 986145543
Principal investigator 1 ABBVIE INC. $2,179.53 06/07/2023 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 998359721
Principal investigator 1 Incyte Corporation $7,096.45 06/03/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040911821
Principal investigator 1 Janssen Research & Development, LLC $10,950.56 05/18/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 986113533
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 05/16/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 986113513
Principal investigator 1 Janssen Research & Development, LLC $1,250.00 05/16/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 986113517
Principal investigator 1 Incyte Corporation $7,205.47 05/03/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040911807
Principal investigator 1 PFIZER INC. $2,056.40 04/27/2023 Non-covered Recipient Entity
NorthShore University Health System
A PHASE 23 TWOPART STUDY TO EVALUATE THE EFFICACY AND LONGTERM SAFETY WITH ORAL ETRASIMOD 2 MG ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATETOSEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRIOR SYSTEMIC TREATMENT FAILURE No dispute reported 06/30/2026 1045958441
Principal investigator 1 Incyte Corporation $2,476.00 04/26/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1040665995
Principal investigator 1 Janssen Research & Development, LLC $6,851.28 04/21/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 986113529
Principal investigator 1 Amgen Inc. $12,204.08 04/20/2023 Non-covered Recipient Entity
NORTHSHORE UNIV HEALTHSYSTEM CLIN T
P3 AD Adolescent Mono No dispute reported 06/30/2026 1029653587
Principal investigator 1 Incyte Corporation $545.16 04/13/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040911795
Principal investigator 1 SANOFI US SERVICES INC. $394.10 04/04/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1036005555
Principal investigator 1 SANOFI US SERVICES INC. $394.10 04/04/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1036005565
Principal investigator 1 SANOFI US SERVICES INC. $394.10 04/04/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1036005575
Principal investigator 1 SANOFI US SERVICES INC. $394.10 04/04/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1036005585
Principal investigator 1 SANOFI US SERVICES INC. $394.10 04/04/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1036005595
Principal investigator 1 SANOFI US SERVICES INC. $394.10 04/04/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1036005603
Principal investigator 1 SANOFI US SERVICES INC. $394.10 04/04/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1036005613
Principal investigator 1 SANOFI US SERVICES INC. $394.10 04/04/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 1036005621
Principal investigator 1 Janssen Research & Development, LLC $964.00 04/03/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 986113521
Principal investigator 1 Janssen Research & Development, LLC $1,656.00 04/03/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 986113525
Principal investigator 1 Incyte Corporation $1,792.00 03/29/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 1040665977
Principal investigator 1 Incyte Corporation $7,959.66 03/29/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040911783
Principal investigator 1 ABBVIE INC. $88.40 03/28/2023 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 998359709
Principal investigator 1 Eli Lilly and Company $1,182.25 03/28/2023 Non-covered Recipient Entity
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1038117653
Principal investigator 1 Janssen Research & Development, LLC $5,895.96 03/27/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 986145535
Principal investigator 1 Janssen Research & Development, LLC $30,033.76 03/20/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 986113509
Principal investigator 1 ABBVIE INC. $65.00 03/16/2023 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 998359705
Principal investigator 1 Eli Lilly and Company $1,725.94 03/09/2023 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1038062207
Principal investigator 1 Eli Lilly and Company $2.02 03/09/2023 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1038076173
Principal investigator 1 Incyte Corporation $12,872.77 03/01/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040911771
Principal investigator 1 Janssen Research & Development, LLC $7,766.55 02/23/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 986145539
Principal investigator 1 Incyte Corporation $662.40 02/16/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040911759
Principal investigator 1 ABBVIE INC. $68.00 02/14/2023 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 998359699
Principal investigator 1 Janssen Research & Development, LLC $138.10 02/13/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 986145537
Principal investigator 1 ABBVIE INC. $2,114.53 02/09/2023 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 998359697
Principal investigator 1 Incyte Corporation $4,921.95 02/01/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1040911747
Principal investigator 1 Janssen Research & Development, LLC $8,618.28 01/30/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 986145541
Principal investigator 1 Janssen Research & Development, LLC $15,750.00 01/26/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 986113501
Principal investigator 1 Janssen Research & Development, LLC $5,945.20 01/23/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 986145533
Principal investigator 1 Janssen Research & Development, LLC $2,974.64 01/20/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 986113505
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $8,571.00 01/05/2023 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Phase II Umbrella AD - A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1027441177
Principal investigator 1 ABBVIE INC. $1,653.67 01/04/2023 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 998359685